Barclays Cuts Estimates on Par Pharmaceutical (PRX); Removing Lovaza Contribution From Model

Article Stock Quotes (1) Comments (0)

Barclays maintains an 'Equalweight' on Par Pharmaceutical (NYSE: PRX) price target of $35.00.

Analyst, Douglas D. Tsao, said, "We our removing a generic Lovaza contribution from our 2012-2016 estimates and now assume no contribution until patent expiry in 2017. Our revised EPS estimates are as follows: 2012 - $3.70 vs previous $3.85; 2013 - $2.92 vs previous $3.26; 2014 - $3.29 vs previous $4.24; 2015 - $3.46 vs previous $3.91; 2016 - $4.80 vs previous $5.25."

For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.

Shares of Par Pharmaceutical closed at $37.01 yesterday, with a 52 week range of $24.85-$42.80.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
• UPDATE: BofA/Merrill Lynch Downgrades Cliffs Natural Resources (CLF) to Underperform
• UPDATE: BofA/Merrill Lynch Upgrades Adobe (ADBE) to Buy

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Barclays

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?